Evidence map›Paper›PMID 39257278›Full record

ArticleEuropean journal of heart failure2024

Heart failure in Europe: Guideline-directed medical therapy use and decision making in chronic and acute, pre-existing and de novo, heart failure with reduced, mildly reduced, and preserved ejection fraction - the ESC EORP Heart Failure III Registry.

Lars H Lund, Maria Generosa Crespo-Leiro, Cécile Laroche, Diana Zaliaduonyte, Aly M Saad, Candida Fonseca, Jelena Čelutkienė, Marija Zdravkovic, Agata M Bielecka-Dabrowa, Piergiuseppe Agostoni and 21 more

Registry-linked trialAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of heart failure, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07403058 (Endovascular Ablation Of The Right Greater Splanchnic Nerve In Subjects Having Heart Failure With Reduced Ejection Fraction), which is not on this map. Cited by 30 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07403058 nanot yet recruitingnot on this mapstarted 2026, after this paper: background citation

Endovascular Ablation Of The Right Greater Splanchnic Nerve In Subjects Having Heart Failure With Reduced Ejection Fraction: Randomized Controlled Feasibility Trial

TypeinterventionalSponsorAxon Therapies, Inc.Ran2026 to 2028Enrolled50ConditionsHeart Failure With Reduced Ejection Fraction (HFrEF)ArmsRight Greater Splanchnic Nerve (GSN) ablation, Sham Control
3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Observational
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Heart failure evidence update 2026.Heart failure reviews · 2026
    Review
  13. Article
  14. Article
  15. Observational
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors.

Lars H LundDepartment of Medicine, Karolinska Institutet, Stockholm, Sweden.ORCID https://orcid.org/0000-0003-1411-4482
Maria Generosa Crespo-LeiroCardiology, Hospital Universitario A Coruña (CHUAC), INIBIC (Institute investigacion Biomedica A Coruña), A Coruña, Spain.
Cécile LarocheEuropean Society of Cardiology, Sophia-Antipolis, France.
Diana ZaliaduonyteAcademy of Medicine, Department of Cardiology, Lithuanian University of Health Sciences, Kaunas, Lithuania.
Aly M SaadCardiovascular Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt.
Candida FonsecaHeart Failure Clinic, Internal Medicine Department, Hospital Sao Francisco Xavier, ULSLO, Lisbon, Portugal.
Jelena ČelutkienėClinic of Cardiac and Vascular Diseases, Institute of Clinical Medicine, Vilnius University, Vilnius, Lithuania.
Marija ZdravkovicUniversity Clinical Hospital Center Bezanijska Kosa, Belgrade, Serbia.
Agata M Bielecka-DabrowaDepartment of Cardiology and Congenital Heart Diseases of Adults, Polish Mother's Memorial Hospital Research Institute (PMMHRI), Lodz, Poland.
Piergiuseppe AgostoniDepartment of Clinical Sciences and Community Health, Cardiovascular Section, University of Milan, Milan, Italy.
Robert G XuerebDepartment of Cardiology, Mater Dei Hospital, Msida, Malta.
Kseniya V NeronovaDepartment of Faculty Therapy Named after M.E. Volsky-M.M. Mirrakhimov, I.K. Akhunbaev Kyrgyz State Medical Academy, Bishkek, Kyrgyzstan.
Malgorzata LelonekDepartment of Noninvasive Cardiology, Medical University of Lodz, Lodz, Poland.
Yuksel CavusogluDepartment of Cardiology, Eskisehir Osmangazi University, Eskisehir, Turkey.
Barnabas GellenDepartment of Cardiology, Heart Failure, ELSAN-Polyclinique de Poitiers, Poitiers, France.
Magdy AbdelhamidDepartment of Cardiovascular Medicine, Kasr AlAiny, Faculty of Medicine, Cairo University, Cairo, Egypt.
Naima HammoudiDepartment of Cardiology, EHS Maouche Hospital-Benaknoun, Algiers, Algeria.
Stefan D AnkerDepartment of Cardiology (CVK), German Heart Center Charité, Berlin, Germany.
Ovidiu ChioncelDepartment of Cardiology, Emergency Institute for Cardiovascular Diseases 'C.C. Iliescu', Bucharest, Romania.
Gerasimos FilippatosDepartment of Cardiology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Mitja LainscakDivision of Cardiology, General Hospital Murska Sobota, Rakičan, Slovenia.
Theresa A McDonaghDepartment of Cardiology, King's College Hospital, London, UK.
Alexandre MebazaaAnesthesia and Critical Care Medicine, Université Paris Cité, Paris, France.
Massimo PiepoliDepartment of Biomedical Sciences for Health, University of Milan, Milan, Italy.
Frank RuschitzkaDepartment of Cardiology, University Heart Center, University Hospital Zurich, Zürich, Switzerland.
Petar M SeferovićSerbian Academy of Sciences and Arts, Belgrade, Serbia.
Gianluigi SavareseDepartment of Medicine, Karolinska Institutet, Stockholm, Sweden.
Marco MetraInstitute of Cardiology, ASST Spedali Civili, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy.
Giuseppe M C RosanoCardiac Academic Group, Chair of Cardiology, St George's University Medical School, London, UK.
Aldo P MaggioniANMCO Research Center - Heart Care Foundation, Florence, Italy.
ESC EORP HF III National Leaders and Investigators

Funding

Abbott FundAmgen FoundationAstraZenecaBayerBoehringer IngelheimBristol Myers Squibb FoundationDaichii Sankyo EuropeEdwards LifesciencesNovartisServierVifor Pharma
6 · The paper itself

Abstract

aimsWe analysed baseline characteristics and guideline-directed medical therapy (GDMT) use and decisions in the European Society of Cardiology (ESC) Heart Failure (HF) III Registry. METHODS AND

resultsBetween 1 November 2018 and 31 December 2020, 10 162 patients with acute HF (AHF, 39%, age 70 [62-79], 36% women) or outpatient visit for HF (61%, age 66 [58-75], 33% women), with HF with reduced (HFrEF, 57%), mildly reduced (HFmrEF, 17%) or preserved (HFpEF, 26%) ejection fraction were enrolled from 220 centres in 41 European or ESC-affiliated countries. With AHF, 97% were hospitalized, 2.2% received intravenous treatment in the emergency department, and 0.9% received intravenous treatment in an outpatient clinic. AHF was seen by most by a general cardiologist (51%) and outpatient HF most by a HF specialist (48%). A majority had been hospitalized for HF before, but 26% of AHF and 6.1% of outpatient HF had de novo HF. Baseline use, initiation and discontinuation of GDMT varied according to AHF versus outpatient HF, de novo versus pre-existing HF, and by ejection fraction. After the AHF event or outpatient HF visit, use of any renin-angiotensin system inhibitor, angiotensin receptor-neprilysin inhibitor, beta-blocker, mineralocorticoid receptor antagonist and loop diuretics was 89%, 29%, 92%, 78%, and 85% in HFrEF; 89%, 9.7%, 90%, 64%, and 81% in HFmrEF; and 77%, 3.1%, 80%, 48%, and 80% in HFpEF.

conclusionUse and initiation of GDMT was high in cardiology centres in Europe, compared to previous reports from cohorts and registries including more primary care and general medicine and regions more local or outside of Europe and ESC-affiliated countries.

Indexed as

Clinical Decision-MakingHeart FailurePractice Guidelines as TopicRegistriesStroke VolumeAcute DiseaseAdrenergic beta-AntagonistsAgedAngiotensin Receptor AntagonistsChronic DiseaseEuropeFemaleGuideline AdherenceHumansMaleMiddle AgedAdrenergic beta-AntagonistsAngiotensin Receptor AntagonistsMineralocorticoid Receptor AntagonistsEjection fractionGuideline‐directed medical therapyHeart failureImplementationQuality of careRegistry

Identifiers

PMID39257278
PMCPMC11683873

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.